Antonio Spanevello, CHEST 2022: Biologics and Unmet Needs in Severe Asthma
Asthma is a chronic heterogenous disease, airway eosinophilic inflammation can be reduced with biologics; however, there remains many unmet needs in the treatment of type-2 low severe asthma. touchRESPIRATORY were delighted to catch up with editorial board member, Prof. Antonio Spanevello (University of Insubria and Maugeri Care and Research Institute, IRCCS Tradate, Varese, Italy) to learn more around the effectiveness of available pharmacological treatments for eosinophilic severe asthma and the unmet needs in treating type 2-low severe asthma.
‘Biologics in non eosinophilic asthma’ was presented at CHEST Congress 2022, 27-29 June 2022.
Questions
- Are pharmacological treatments able to reduce airway inflammation in eosinophilic severe asthma? (0:27)
- What are the unmet needs in the treatment of patients with type 2-low severe asthma? (1:33)
Disclosures: Antonio Spanevello discloses consulting for GSK, Chiesi, MSD, Astrazeneca, Sanofi and Menarini; receiving grant/ research support from GSK and Chiesi; serving on advisory boards for GSK, Chiesi, MSD, Astrazeneca, Sanofi and Menarini; and receiving honoraria from GSK, Chiesi, MSD, Astrazeneca, Sanofi and Menarini.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the CHEST meeting 2022.
